UBS Microcap Fund (UBS0057AU) Report & Performance

What is the UBS Microcap Fund fund?

UBS Microcap Fund aims to provide investors with capital growth over the long term from a portfolio of micro company shares that we believe are being undervalued by the market, based on our assessment of the companies’ future cash flows.

  • The Fund is actively managed and invests primarily in a portfolio of 35-65 stocks with a market capitalization of generally less than $250m.
  • Eligible investments of the Fund comprise listed Australian and New Zealand securities, unlisted investments with the intention to float within six months.
  • The Fund may invest in financial derivatives to gain exposure to the Australian and New Zealand sharemarket or to manage investment risk.

Growth of $1000 Investment Over Time

Performance Report

Peer Comparison Report

Peer Comparison Report

Latest News & Updates For UBS Microcap Fund

UBS Microcap Fund Fund Commentary September 30, 2023

After fees and expenses, the Portfolio declined by 4.14% during the month, underperforming its benchmark by 11 bps.

The largest positive contributors were Generation Development Group, Monash IVF and Leo Lithium (not held). Generation Development Group jumped on speculation that the business may be a takeover target given recent consolidation in the funds management industry. Monash IVF traded higher after the release of Medicare statistics for August which showed total cycle growth of 20.3% on the prior corresponding period. Leo Lithium (not held) was suspended from listing pending correspondence from the Mali government in relation to their Goulamina Lithium project.

The largest negative contributors were Botanix Pharmaceuticals, Paladin Energy (not held) and XRF Scientific. Botanix Pharmaceuticals traded lower as FDA approval for their novel drug Sofpironium Bromide was delayed pending additional information regarding patient use instructions. Paladin Energy (not held) traded higher on the back of a stronger underlying Uranium price. Lastly XRF Scientific was sold off despite no stock specific news.

READ HISTORICAL PERFORMANCE COMMENTARIES

Product Snapshot

  • Performance Review
  • Product Overview
  • Peer Comparison
  • Product Details

Performance Review

Fund Name Last Month
? Returns after fees in the most recent (last) month).
3 Months Return
? Returns after fees in the most recent 3 months.
1 Year Return
? Trailing 12 month returns.
3 Years Average Return
? Average Annual returns from the last 3 years.
Since Inc. Average Return
? Average (annualised) returns since inception
1 Year Std. Dev. (Annual)
? The standard deviation (or annual volatility) of the last 12 months.
3 Years Std. Dev. (Annual)
? The average standard deviation (or annual volatility) from the last 3 years.
Since Inc. Std. Dev. (Annual)
? The average standard deviation (or annual volatility) since the fund inception.
1 Year Max Drawdown
? The maximum drawdown in the last 12 months - a drawdown is a peak-to-trough decline during a specific period for an investment, trading account, or fund.
3 Year Max Drawdown
? The maximum drawdown in the last 36 months - a drawdown is a peak-to-trough decline during a specific period for an investment, trading account, or fund.
Since Inc. Max Drawdown
? The maximum drawdown since inception - a drawdown is a peak-to-trough decline during a specific period for an investment, trading account, or fund.
UBS Microcap Fund4.59%6.78%21.47%2.9%12.76%10.4%14.05%16.53%-5.55%-23.75%-34.3%

Product Overview

Peer Comparison

Product Details

Product Due Diligence

What is UBS Microcap Fund

UBS Microcap Fund is an Managed Funds investment product that is benchmarked against ASX Index Small Ordinaries Index and sits inside the Domestic Equity - Small Cap Index. Think of a benchmark as a standard where investment performance can be measured. Typically, market indices like the ASX200 and market-segment stock indexes are used for this purpose. The UBS Microcap Fund has Assets Under Management of 35.17 M with a management fee of 1.2%, a performance fee of 20.00% and a buy/sell spread fee of 0.7%.

How has the investment product performed recently?

How is risk measured in this investment product?

What is the relative performance of the investment product?

Does the investment product produce Alpha over its Peers?

What are similar investment products?

What level of diversification will UBS Microcap Fund provide?

How do I compare the investment product with its peers?

How do I compare the UBS Microcap Fund with the ASX Index Small Ordinaries Index?

Can I sort and compare the UBS Microcap Fund to do my own analysis?

Has the UBS Microcap Fund been independently verified by SMSF Mate?

How can I invest in UBS Microcap Fund?

How do I get in contact with the UBS Microcap Fund?

Comments from SMSF Mates

Historical Performance Commentary

Performance Commentary - August 31, 2023

After fees and expenses, the Portfolio increased by 1.70% during the month, outperforming its benchmark by 301 bps.

The largest positive contributors were Botanix Pharmaceuticals, Energy One and Laserbond. Botanix Pharmaceuticals traded higher as the targeted FDA approval date for their novel drug Sofpironium Bromide was reaffirmed for end of September 2023. Energy One received a non-binding indicative offer for their business at $5.85/share being a 44% premium to its last traded price. Laserbond provided a strong FY23 result with revenue up 25.7% on pcp and net profit after tax up 31.1%.

The largest negative contributors were NextEd, XRF Scientific and PeopleIn. Tertiary education provider NextEd traded lower following a trading update highlighting the negative implications of the temporary COVID-19, 408 Visa on their business which has since ceased. XRF scientific traded lower after reaching all time highs. PeopleIn was sold off after missing their pre-announced EBITDA guidance range of $62m-$66m for FY23, generating $60.9m.

Performance Commentary - July 31, 2023

Performance Commentary - June 30, 2023

Performance Commentary - May 31, 2023

Performance Commentary - April 30, 2023

Performance Commentary - March 31, 2023

Performance Commentary - February 28, 2023

Kind words from Aussies managing
their own self funded futures

  • SMSF Mate is a unique website because it has ideas about how to approach SMSFs, insurance and other financial topics that come straight from first hand experience. It's much more useful than what you find on all the other financial websites that just offer generic info that you could easily get on the ATO's website. It's also nice to know there's no financial incentive behind the information, it's legitimately there to help people understand self-managed super funds and how to get the most out of them, not to get an affiliate commission from a broker or other financial services provider. The investment product information is also incredibly useful, I've never seen this kind of functionality on any other website that let's you look at such a wide range of products, sort by what info is most interesting or important to you, and subscribe to updates for different funds and financial products all in one place. Definitely worth checking out if you own or are considering an SMSF!

    David G, Self-Employed, SMSF Owner